Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

NCT00439556 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

CD20 Positive
Hematopoietic and Lymphoid Cell Neoplasm
Lymphocytic Neoplasm
Lymphoma

Interventions

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
BIOLOGICAL: Anti-Thymocyte Globulin
DRUG: Bortezomib
DRUG: Carmustine
DRUG: Cytarabine
DRUG: Etoposide
BIOLOGICAL: Filgrastim
DRUG: Melphalan
DRUG: Methotrexate
BIOLOGICAL: Rituximab
DRUG: Tacrolimus

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]